Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820078 | 0.83 | — | — | |
| SCHEMBL18736515 | 0.81 | TSHR (0.38) | TSHRALDH1A1LMNATP53 | |
| SCHEMBL10799136 | 0.80 | TSHR (0.56) | TSHRALDH1A1LMNATP53CA1 | |
| SCHEMBL9174837 | 0.80 | TSHR (0.56) | TSHRALDH1A1LMNATP53CA1 | |
| SCHEMBL19675034 | 0.80 | ALDH1A1 (0.33) | TSHRALDH1A1LMNATP53 | |
| SCHEMBL1591759 | 0.79 | — | — | |
| SCHEMBL29228018 | 0.77 | TSHR (0.45) | TSHRALDH1A1LMNATP53CA1 | |
| SCHEMBL1410633 | 0.75 | — | — | |
| SCHEMBL4312900 | 0.73 | TSHR (0.43) | TSHRALDH1A1LMNATP53 | |
| SCHEMBL9558123 | 0.71 | CA1 (0.55) | TSHRALDH1A1LMNATP53CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | NEUROVIVE PHARMACEUTICAL AB (SE) | 2019-06-04 | — | — | US | disclosed |
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | NEUROVIVE PHARMACEUTICAL AB (SE) | 2019-06-04 | — | — | US | disclosed |
| EP-2903609-B1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-12-06 | — | — | EP | disclosed |
| EP-2903609-B1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-12-06 | — | — | EP | disclosed |
| US-9670175-B2 | Protected succinates for enhancing mitochondrial ATP-production | Neurovive Pharmaceuticals AB (SE) | 2017-06-06 | — | — | US | disclosed |
| US-9670175-B2 | Protected succinates for enhancing mitochondrial ATP-production | Neurovive Pharmaceuticals AB (SE) | 2017-06-06 | — | — | US | disclosed |
| US-9670175-B2 | Protected succinates for enhancing mitochondrial ATP-production | Neurovive Pharmaceuticals AB (SE) | 2017-06-06 | — | — | US | disclosed |
| US-20170105960-A1 | Prodrugs of Succinic Acid for Increasing ATP Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170105960-A1 | Prodrugs of Succinic Acid for Increasing ATP Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | Abliva Ab (SE) | 2017-04-13 | — | — | US | disclosed |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | Abliva Ab (SE) | 2017-04-13 | — | — | US | disclosed |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | Abliva Ab (SE) | 2017-04-13 | — | — | US | disclosed |
| WO-2015155238-A1 | SUCCINATE PRODRUGS FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS OR DRUG-INDUCED SIDE-EFFECTS DUE TO COMPLEX I-RELATED IMPAIRMENT OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-10-15 | — | — | WO | disclosed |
| US-20150259317-A1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | MITOPHARM LTD (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259317-A1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | MITOPHARM LTD (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259317-A1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | MITOPHARM LTD (GB) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170105960-A1 | Prodrugs of Succinic Acid for Increasing ATP Production | SLC25A1, SLC25A11, SLC25A21 | TSHR 4719/4885ALDH1A1 1575/4885LMNA 3101/4885 |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | CS, MDH2, SLC25A11 | TSHR 4279/4885ALDH1A1 309/4885LMNA 1449/4885 |
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | CS, MDH2, SLC25A11 | TSHR 4279/4885ALDH1A1 309/4885LMNA 1449/4885 |
| US-20150259317-A1 | PROTECTED SUCCINATES FOR ENHANCING MITOCHONDRIAL ATP-PRODUCTION | CS, SDHA, MDH2 | TSHR 4479/4885ALDH1A1 612/4885LMNA 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.